Bio-Rad Laboratories Inc. - Ordinary Shares - Class A
BIO
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.94B
Close$
$147.63
60% downside
Current Fair Value
60% downsideOvervalued by 60% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.94 Billion |
|---|---|
| Enterprise Value | $10.70 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $27.87 |
| Beta | 1.07 |
| Outstanding Shares | 26,746,000 |
Return
| Return on Equity | 3.10% |
|---|---|
| Return on Assets | 2.17% |
| Return on Invested Capital | -6.18% |
Valuation & Multiples
| P/E Ratio | 44.31 |
|---|---|
| PEG | 262.75 |
| Price to Sales | 3.85 |
| Price to Book Ratio | 1.38 |
| Enterprise Value to Revenue | 4.13 |
| Enterprise Value to EBIT | -18.63 |
| Enterprise Value to Net Income | 48 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 0.18 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$1.75
Average shareholder expectationRevenue Estimate
$623.99 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$2.23
Average shareholder expectationRevenue Estimate
$650.64 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1172▼ 8.43% |
|---|---|
| Total Calls | 51,200▲ 268.35% |
| Total Puts | 6,000▲ 114.29% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 73.29%▼ 0.84% |
|---|---|
| Total Invested | $5.76B▲ 3.34% |
| Investors Holding | 405▲ 5.00% |
ESG Score
No data
About Bio-Rad Laboratories Inc.
CEO: Norman Schwartz